Reprogramming and Epigenetic Modifications: Unraveling the Role of Histone Lactylation in Atherosclerosis
Biomolecules · 19.11.2026 · 16 (11) · 1681
DOI: 10.3390/biom16111681 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecules, online erschienen am 19.11.2026. Verfasst von Xiaoqin Mi und 9 weiteren Autor:innen. Die Arbeit nennt 213 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Department of Science and Technology of Guizhou Province, Guizhou Provincial Science and Technology Department.
Abstract (Originalsprache)
Lactylation links cellular metabolism to histone regulation and nonhistone protein function; however, its functional consequences in atherosclerosis depend on the modified substrate, target residue, cell type, and disease stage. This narrative review distinguishes direct atherosclerosis evidence from cardiovascular but non-atherosclerosis evidence and cross-disease mechanistic context, framing mechanistic claims accordingly. Direct evidence in atherosclerosis implicates several pathogenic pathways, including endothelial H3K18 lactylation at NF-κB pathway and SNAI1 promoters, SLC22A6- and ACSS1-driven H3K9 lactylation, lactate- and AARS1-dependent FOXO1 lactylation under atheroprone flow, H4K12 lactylation at CDKN1A during endothelial senescence, and an H3K18 lactylation–METTL3 axis in macrophage ferroptosis. Conversely, direct evidence also supports atheroprotective pathways, notably nonhistone MeCP2 K271 lactylation in endothelial cells and macrophages. Observations from myocardial repair, valvular and medial calcification, aortic aneurysm, pulmonary hypertension, and oncology provide mechanistic context rather than direct proof of plaque-specific biology. Furthermore, we examine the interplay between lactylation and acetylation, methylation, and RNA modifications—including scenarios where lactylation functions upstream of acetylation—and critically evaluate the capabilities and limitations of current analytical methods. Key methodological considerations include lactyl-donor stoichiometry and site occupancy; antibody cross-reactivity; resolution of L-lactyl, D-lactyl, and carboxyethyl lysine isomers; mass-spectrometric site localization; chromatin profiling against matched acetylation controls; and stable-isotope tracing. Finally, we propose an integrative translational framework that pairs peripheral mononuclear cell and plaque sampling with single-cell and spatial multi-omics, strictly distinguishing lactate sensing from site-specific protein lactylation detection. To date, no clinically validated lactylation biomarker or lactylation-targeted therapy exists for atherosclerosis, and lactate abundance cannot be conflated with protein lactylation. Clinical translation ultimately requires site-specific causal validation in plaque-relevant models and prospective human cohorts.
Förderung
- National Natural Science Foundation of China
- Department of Science and Technology of Guizhou Province
- Guizhou Provincial Science and Technology Department
- Zunyi City Municipal and University Joint Science and Technology Funding Project
- Guizhou Provincial Key Basic Research Program
- Guizhou Key Laboratory of Modern Traditional Chinese Medicine Creation
Zitieren
APA
Mi, X., Gu, R., Wu, C., Luo, F., Guoyang, T., Xu, Y., Guo, X., Liu, L., Tang, M., & Nie, X. (2026). Reprogramming and Epigenetic Modifications: Unraveling the Role of Histone Lactylation in Atherosclerosis. Biomolecules, 16(11), 1681. https://doi.org/10.3390/biom16111681
Vancouver
Mi X, Gu R, Wu C, Luo F, Guoyang T, Xu Y, et al. Reprogramming and Epigenetic Modifications: Unraveling the Role of Histone Lactylation in Atherosclerosis. Biomolecules. 2026;16(11):1681. doi:10.3390/biom16111681
BibTeX
@article{Mi2026,
author = {Mi, Xiaoqin and Gu, Rifang and Wu, Caozhen and Luo, Fengqin and Guoyang, Taotao and Xu, Ya and Guo, Xiuying and Liu, Lele and Tang, Ming and Nie, Xuqiang},
title = {Reprogramming and Epigenetic Modifications: Unraveling the Role of Histone Lactylation in Atherosclerosis},
journal = {Biomolecules},
year = {2026},
volume = {16},
number = {11},
pages = {1681},
doi = {10.3390/biom16111681}
}
EUVIMED